News

Ozempic maker goes to war with ‘fake’ copycat jabs as sales slow
The maker of Ozempic and Wegovy has declared war on “fake” copycat weight-loss jabs as it battles a sales slowdown.
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S.
Novo Nordisk warns copycat drugs continue weighing on sales
Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...
Novo Nordisk shares dip further as Wegovy gains nearly erased
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
Weight-loss jab Wegovy sees another prescription boost after ban on copycats
Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...